Phase II study of tepotinib in NSCLC patients with METex14 mutations.

9005Background: MET exon 14 skipping (METex14) mutations - reported in 3~4% of NSCLC patients (pts) - are activating, sensitive to MET inhibition and can be conveniently detected using liquid biops...